Jan 25 (Reuters) - The European health regulator's advisory panel issued a negative opinion for PTC Therapeutics' drug to treat Duchenne muscular dystrophy (DMD), an inherited progressive muscle-wasting disorder, the company said on Thursday. (Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
The $50 million purchase could turn into Nvidia's biggest investment.
These proven wealth builders could be exactly what you're searching for right now.
The property report includes 85 major metropolitan areas in the U.S. with populations of at least 750,000.
$10,000 to each of these companies could deliver major returns over the next decade.
Lots of companies are trying to capitalize on the AI revolution, but one company sticks out from the pack.
Walmart's CEO went from earning $6.50 an hour to $25 million a year—here are his three tips for climbing the corporate ladder like him
There are benefits to investing in stocks that have reasonable multiples and aren't as dependent on future earnings growth to justify their valuations.
The JPMorgan Nasdaq Equity Premium Income ETF offers a compelling blend of income and upside to my portfolio.